earningsconfidence high
CalciMedica reports Q1 net income $5.0M; FDA feedback on Auxora pivotal program expected Q2 2026
CalciMedica, Inc.
2026-Q1 EPS reported
$0.30
- Net income $5.0M ($0.31 basic) vs net loss $5.0M a year ago; cash $8.2M as of March 31, 2026.
- R&D expenses $3.5M, G&A $2.1M; other income $10.6M from fair value adjustments on warrants and note.
- FDA feedback on pivotal program design for Auxora in acute pancreatitis expected in Q2 2026.
- IND submission for oral CRAC inhibitor CM5480 in pulmonary hypertension anticipated in 2027.
- Phase 2b CARPO results published: Auxora showed 100% reduction in new-onset severe respiratory failure (p<0.05).
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.